HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
Loading market information…
HKSE · 2181.HK · HKD
Stock price, earnings
Quote as of Oct 29, 2026, 06:29 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Mabpharm Limited’s quoted price sits in the lower half of its reported 52-week range, 46.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Mabpharm Limited’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mabpharm Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
HK$67.00+HK$0.10 (+0.15%)
Keymed Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.35% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$18.12-HK$0.48 (-2.58%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 37.9% below the high.
HK$23.60-HK$1.36 (-5.45%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
